PREdicting Failure of Non-inVasIve Ventilatory Support Using Non-invaSIve mONitoring in Non-intubated Patients With Acute Hypoxemic Respiratory Failure or Post-extubation Failure. The PREVISION Study (PREVISION)

May 15, 2025 updated by: Unity Health Toronto

PREdicting Failure of Non-inVasIve Ventilatory Support Using Non-invaSIve mONitoring in Non-intubated Patients With Acute Hypoxemic Respiratory Failure or Post-extubation Failure: the PREVISION Study

The goal of this observational study is to assess the potential non-invasive tools (e.g. regional ventilation, respiratory muscle response, lung mechanic's parameters) to identify the risk of failure when using high flow nasal cannula (HFNC) or non-invasive ventilation (NIV).

The main question, it aims to answer is:

Does abnormal regional ventilation could predict HFNC or NIV failure?

Study Overview

Detailed Description

This is a single-center, prospective, physiological study.

The study will enroll patient who has used either HFNC or NIV for the indications of 1. to prevent worsening acute hypoxemic respiratory failure or 2. to prevent reintubation. Once being confirmed to meet the inclusion criteria, the research team will apply the electrical impedance tomography (EIT) on the patient and start recording for 5-10 minutes as well as perform diaphragm and parasternal intercostal muscle ultrasound when the patient is using HFNC or NIV. The current HFNC or NIV setting, some lung mechanic's parameters (e.g. rapid shallow breathing trial (RSBI), negative airway pressure generated during the first 100 milisecond (P0.1), end-expiratory occlusion pressure(ΔPocc) derived from NIV machine), patient's characteristic, dyspnea scores (intensive care respiratory distress observation scale, IC-RDOS; work of breathing scale; self-report of dyspnea visual analog scale, D-VAS), ICU and hospital length of stay will be also collected.

The investigator will use EIT to visualize where air goes in the patient's lung and inspiratory muscle ultrasonography (diaphragm and parasternal intercostal muscle) to visualize the muscle activities when using HFNC or NIV. EIT is a measurement often used in the ICU since it allows easy visualization and is a non-invasive technique. The sensors measure electrical current changes during inspiration and expiration and will not cause any pain or radiation concerns. The EIT belt (3-cm diameter) will be placed around the chest without causing adverse event/discomfort/pain.

The duration of study will be approximately 30 minutes. The study will be conducted one time for one enrolled patient.

HFNC or NIV (device) failure is considered as either intubation/reintubation or death, whatever has come first. It will be followed up to 7 days.

The investigators will proceed with the measurements only with agreement from the clinical team. The investigators will analyze the data collected offline with a dedicated software afterwards.

After these study procedures are completed, data will also be collected from the participant's chart and combined with relevant information from the HFNC or NIV settings and vital functions. Confidentiality will be maintained throughout the entire study.

Study Type

Observational

Enrollment (Estimated)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Toronto, Ontario, Canada, M5B 1W8

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patient who is using high flow nasal cannula (HFNC) or non-invasive ventilation (NIV) to either prevent 1. intubation in the context of acute hypoxemic respiratory failure or 2. reintubation in the context of high risk group of extubation.

Description

Inclusion Criteria:

  • Age of ≥ 18 years
  • Using NIV or HFNC anywhere in the hospital

Exclusion Criteria:

  • Chronic CO2 retention
  • Neuromuscular disorder
  • Requiring home NIV (CPAP or BIPAP)
  • Tracheostomy
  • Contraindication to EIT placement: pacemaker/defibrillator implantation, burns at the area of EIT placement

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference in regional ventilation distribution (%)
Time Frame: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
The primary endpoint is to assess regional ventilation distribution (%) when using HFNC or NIV to predict a device failure.
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diaphragm or parasternal intercostal muscle thickening fraction
Time Frame: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
To assess ultrasound measurement of inspiratory muscle activity when using HFNC or NIV to predict a device failure.
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
Rapid shallow breathing index (RSBI) in mL/breaths/min
Time Frame: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
To assess non-invasive respiratory - rapid shallow breathing index (RSBI) derived from NIV to predict a device failure.
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
Respiratory drive using negative airway pressure generated during the first 100 millisecond (P0.1)
Time Frame: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
To assess respiratory drive - using negative airway pressure generated during the first 100 millisecond (P0.1) in cmH2O to predict device failure.
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
Respiratory effort using end-expiratory airway occlusion pressure (ΔPocc)
Time Frame: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
To assess respiratory effort using end-expiratory airway occlusion pressure (ΔPocc) in cmH2O to predict device failure
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
The intensive care respiratory distress observation scale (IC-RDOS)
Time Frame: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
To assess the level of dyspnea using intensive care respiratory distress observation scale (IC-RDOS) to predict a device failure. There is no minimum or maximum range depending on patient's heart rate, the higher score means worse outcome. When the score ≥ 2.4, it likely indicates clinically important dyspnea requiring clinical management.
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
The work of breathing scale
Time Frame: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
To assess the work of breathing scale to predict a device failure. Minimum is 3 and maximum is 12, the higher score means worse outcome. When the score > 4, it likely indicates severe respiratory distress.
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
Self-report of dyspnea visual analog scale (D-VAS)
Time Frame: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
To assess self-report of dyspnea visual analog scale (D-VAS) to predict a device failure. Minimum is 0 and maximum is 10, the higher score means worse outcome. When the score > 3, it likely indicates dyspnea and being used for quality of palliative care unit
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 27, 2025

Primary Completion (Estimated)

June 1, 2025

Study Completion (Estimated)

June 1, 2025

Study Registration Dates

First Submitted

November 25, 2024

First Submitted That Met QC Criteria

November 28, 2024

First Posted (Actual)

December 4, 2024

Study Record Updates

Last Update Posted (Estimated)

May 20, 2025

Last Update Submitted That Met QC Criteria

May 15, 2025

Last Verified

May 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Weaning Failure

Subscribe